GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO) Financials
GLAXO.BO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2025 | ? | -19.5 billion |
| March 31, 2025 | 41.1 billion | 21.6 billion |
| Dec. 31, 2024 | ? | -16.7 billion |
| Sept. 30, 2024 | 37.5 billion | 20.7 billion |
GLAXO.BO Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2025 | ? | ? |
| March 31, 2025 | ? | ? |
| Dec. 31, 2024 | ? | ? |
| Sept. 30, 2024 | ? | ? |
GLAXO.BO Net Income
| Date | Net Income |
|---|---|
| June 30, 2025 | 2.1 billion |
| March 31, 2025 | 2.6 billion |
| Dec. 31, 2024 | 2.3 billion |
| Sept. 30, 2024 | 2.5 billion |
GLAXO.BO Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2025 | 25.0 billion | - | - |
| March 31, 2025 | 25.0 billion | 24.9 million | 99.5 million |
| Dec. 31, 2024 | 21.1 billion | - | - |
| Sept. 30, 2024 | 21.1 billion | 41.8 million | 147.9 million |
GLAXO.BO Shares Outstanding
GLAXO.BO Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2025 | - | - | 1.5 billion | - |
| March 31, 2025 | - | 26.1 million | 2.8 billion | 1.2 billion |
| Dec. 31, 2024 | - | - | 1.2 billion | - |
| Sept. 30, 2024 | - | - | 1.5 billion | - |
GLAXO.BO Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2025 | 8.1 billion | 2.9 billion |
| March 31, 2025 | 9.7 billion | 3.7 billion |
| Dec. 31, 2024 | 9.5 billion | 3.6 billion |
| Sept. 30, 2024 | 10.1 billion | 3.8 billion |
GLAXO.BO
Price: ₹2,332.85
Dividend Yield: 1.67%
Forward Dividend Yield: 2.44%
Payout Ratio: 84.68%
Dividend Per Share: 57.00 INR
Earnings Per Share: 56.30 INR
P/E Ratio: 44.63
Exchange: BSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Market Capitalization: 425.7 billion
Average Dividend Frequency: 1
Years Paying Dividends: 26
DGR3: 30.00%
DGR5: 30.00%
DGR10: 9.61%